461 related articles for article (PubMed ID: 23264315)
1. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.
Rosenblum A; Cruciani RA; Strain EC; Cleland CM; Joseph H; Magura S; Marsch LA; McNicholas LF; Savage SR; Sundaram A; Portenoy RK
J Opioid Manag; 2012; 8(6):369-82. PubMed ID: 23264315
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
[TBL] [Abstract][Full Text] [Related]
3. Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.
Lucas GM; Young A; Donnell D; Richardson P; Aramrattana A; Shao Y; Ruan Y; Liu W; Fu L; Ma J; Celentano DD; Metzger D; Jackson JB; Burns D;
Drug Alcohol Depend; 2014 Sep; 142():139-45. PubMed ID: 24999060
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
[TBL] [Abstract][Full Text] [Related]
5. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
Altice FL; Bruce RD; Lucas GM; Lum PJ; Korthuis PT; Flanigan TP; Cunningham CO; Sullivan LE; Vergara-Rodriguez P; Fiellin DA; Cajina A; Botsko M; Nandi V; Gourevitch MN; Finkelstein R;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S22-32. PubMed ID: 21317590
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
[TBL] [Abstract][Full Text] [Related]
7. The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample.
Nielsen S; Hillhouse M; Weiss RD; Mooney L; Sharpe Potter J; Lee J; Gourevitch MN; Ling W
Am J Addict; 2014; 23(4):343-8. PubMed ID: 24112096
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine-naloxone therapy in pain management.
Chen KY; Chen L; Mao J
Anesthesiology; 2014 May; 120(5):1262-74. PubMed ID: 24509068
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
[TBL] [Abstract][Full Text] [Related]
10. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
Mitchell MM; Schwartz RP; Choo TH; Pavlicova M; O'Grady KE; Gryczynski J; Stitzer ML; Nunes EV; Rotrosen J
Drug Alcohol Depend; 2021 Feb; 219():108422. PubMed ID: 33352487
[TBL] [Abstract][Full Text] [Related]
11. Buprenorphine alone or with naloxone: Which is safer?
Kelty E; Cumming C; Troeung L; Hulse G
J Psychopharmacol; 2018 Mar; 32(3):344-352. PubMed ID: 29433352
[TBL] [Abstract][Full Text] [Related]
12. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients.
Vergara-Rodriguez P; Tozzi MJ; Botsko M; Nandi V; Altice F; Egan JE; O'Connor PG; Sullivan LE; Fiellin DA;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S62-7. PubMed ID: 21317596
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
[TBL] [Abstract][Full Text] [Related]
14. Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058.
Lucas GM; Beauchamp G; Aramrattana A; Shao Y; Liu W; Fu L; Jackson JB; Celentano DD; Richardson P; Metzger D;
Int J Drug Policy; 2012 Mar; 23(2):162-5. PubMed ID: 21852093
[TBL] [Abstract][Full Text] [Related]
15. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.
Neumann AM; Blondell RD; Jaanimägi U; Giambrone AK; Homish GG; Lozano JR; Kowalik U; Azadfard M
J Addict Dis; 2013; 32(1):68-78. PubMed ID: 23480249
[TBL] [Abstract][Full Text] [Related]
16. Sublingual buprenorphine-naloxone precipitated withdrawal-A case report with review of literature and clinical considerations.
Bhatia G; Sarkar S
Asian J Psychiatr; 2020 Oct; 53():102121. PubMed ID: 32460142
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.
Schackman BR; Leff JA; Polsky D; Moore BA; Fiellin DA
J Gen Intern Med; 2012 Jun; 27(6):669-76. PubMed ID: 22215271
[TBL] [Abstract][Full Text] [Related]
18. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.
Korthuis PT; Fiellin DA; Fu R; Lum PJ; Altice FL; Sohler N; Tozzi MJ; Asch SM; Botsko M; Fishl M; Flanigan TP; Boverman J; McCarty D;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S83-90. PubMed ID: 21317600
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.
Parran TV; Adelman CA; Merkin B; Pagano ME; Defranco R; Ionescu RA; Mace AG
Drug Alcohol Depend; 2010 Jan; 106(1):56-60. PubMed ID: 19717249
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine-naloxone Versus Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy.
Perry BN; Vais S; Boateng JO; Jain M; Wachman EM; Saia KA
J Addict Med; 2022 Nov-Dec 01; 16(6):e399-e404. PubMed ID: 35916423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
